Who are the top shareholders of the Chandra Bhagat?

The top shareholders of Chandra Bhagat include Hemant Chandravadan Bhagat with 35.5%, Team Anamika Algo Limited at 9.5%, and individual investors holding 11.16%. There are no pledged promoter holdings or mutual funds invested in the company.

The top shareholders of Chandra Bhagat include the promoters, with Hemant Chandravadan Bhagat holding the largest share at 35.5%. The highest public shareholder is Team Anamika Algo Limited, which owns 9.5%. Additionally, individual investors collectively hold 11.16% of the shares. There is also one foreign institutional investor (FII) that holds 0.61% of the company's shares. Notably, there are no pledged promoter holdings and no mutual funds currently invested in the company.

how big is Chandra Bhagat?

As of Jun 05, Chandra Bhagat Pharma Ltd has a market capitalization of 46.00 Cr, classifying it as a Micro Cap company. There is no available financial data for the latest four quarters, but as of March 2024, Shareholder's Funds are valued at 29.01 Cr, with Total Assets of 101.78 Cr.

Market Cap: As of Jun 05, Chandra Bhagat Pharma Ltd has a market capitalization of 46.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid Consolidated or Standalone financial data available for the latest four quarters, including figures for Net Sales and Net Profit.<BR><BR>Balance Sheet Snapshot: This is Standalone data for the reporting period of March 2024. The Shareholder's Funds are valued at 29.01 Cr, and the Total Assets amount to 101.78 Cr.

Who are in the management team of Chandra Bhagat?

As of March 2021, the management team of Chandra Bhagat includes Hemant C Bhagat (Chairman & Managing Director), Pranav H Bhagat (Whole-time Director), Prachi Pranav Bhagat (Director & CFO), Ravindra Gajanan Awati (Independent Director), and Abha Praveen Doshi (Independent Director). They are responsible for the company's governance and strategic direction.

As of March 2021, the management team of Chandra Bhagat includes the following individuals:<BR><BR>1. Hemant C Bhagat - Chairman & Managing Director<BR>2. Pranav H Bhagat - Whole-time Director<BR>3. Prachi Pranav Bhagat - Director & CFO<BR>4. Ravindra Gajanan Awati - Independent Director<BR>5. Abha Praveen Doshi - Independent Director<BR><BR>These members play key roles in the governance and strategic direction of the company.

What does Chandra Bhagat do?

Chandra Bhagat Pharma Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, incorporated in 2003 and converted to a Public Limited Company in 2019. It currently has no reported sales or profit data, with a market cap of Rs 46 Cr and a P/E ratio of 42.00.

Overview:<BR>Chandra Bhagat Pharma Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>The company was incorporated in 2003 as "Chandra Bhagat Pharma Private Limited" and later converted to a Public Limited Company, changing its name to "Chandra Bhagat Pharma Limited" on March 20, 2019. There is no sales or profit data reported for the latest quarter.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: Rs 46 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 42.00<BR>Industry P/E: 28<BR>Dividend Yield: 0.00%<BR>Debt Equity: 0.40<BR>Return on Equity: 3.03%<BR>Price to Book: 1.64<BR><BR>Contact Details:<BR>Address: Not available<BR>Phone: Not available<BR>Email: Not available<BR>Website: Not available

When is the next results date for Chandra Bhagat?

No Upcoming Board Meetings

Has Chandra Bhagat declared dividend?

No Dividend History Available

Who are the peers of the Chandra Bhagat?

Chandra Bhagat's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, and others. While Sun Pharma, Cipla, and Dr Reddy's Labs show excellent management and growth, Chandra Bhagat has below average growth and a 1-year return of -42.15%.

Peers: The peers of Chandra Bhagat are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Vista Pharma., Guj. Terce Labs., ANG Lifesciences, and Shree Ganesh Bio.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and the rest have below average management risk. Growth is excellent at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while below average growth is found at Divi's Lab., Torrent Pharma, Vista Pharma., Chandra Bhagat, Guj. Terce Labs., ANG Lifesciences, and Shree Ganesh Bio. Excellent capital structure is noted at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while good capital structure is seen at Torrent Pharma, and below average capital structure is present at Divi's Lab., Vista Pharma., Chandra Bhagat, Guj. Terce Labs., ANG Lifesciences, and Shree Ganesh Bio.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while Vista Pharma. has the lowest at -23.81%. Chandra Bhagat's 1-year return is -42.15%, which is significantly lower than both. Additionally, the six-month return is negative for Vista Pharma., Chandra Bhagat, Guj. Terce Labs., ANG Lifesciences, and Shree Ganesh Bio.

Is Chandra Bhagat overvalued or undervalued?

As of May 30, 2025, Chandra Bhagat's valuation has been downgraded to risky due to overvaluation, with a PE ratio of 42.25 and an EV to EBITDA of -36.70, significantly underperforming its peers and the market.

As of 30 May 2025, the valuation grade for Chandra Bhagat has moved from does not qualify to risky, indicating a significant downgrade in its investment attractiveness. The company is currently considered overvalued, especially when compared to its peers. Key ratios include a PE ratio of 42.25, an EV to EBITDA of -36.70, and a ROE of 3.03%. <BR><BR>In comparison, Sun Pharmaceutical Industries Ltd. has a PE ratio of 35.25 and an EV to EBITDA of 24.91, while Cipla Ltd. shows a more favorable PE of 22.99 and an EV to EBITDA of 15.93, both suggesting better valuation metrics. Additionally, Chandra Bhagat's stock has underperformed significantly, with a year-to-date return of -15.15% compared to a 5.58% return for the Sensex, reinforcing the notion that the stock is overvalued in its current state.

What is the technical trend for Chandra Bhagat?

As of June 4, 2025, Chandra Bhagat's technical trend is mildly bearish, with conflicting signals from indicators like the weekly MACD being mildly bullish and the monthly MACD remaining bearish, while daily moving averages also suggest caution.

As of 4 June 2025, the technical trend for Chandra Bhagat has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish. The Bollinger Bands and KST are both mildly bearish on the weekly and monthly time frames. The moving averages on the daily chart are bearish, which adds to the overall cautious outlook. The Dow Theory shows a mildly bullish signal on the weekly but is bearish on the monthly. The On-Balance Volume (OBV) is mildly bullish on both weekly and monthly charts, suggesting some accumulation. Overall, the current technical stance is mildly bearish, with key indicators such as the daily moving averages and monthly MACD contributing to this view.

How has been the historical performance of Chandra Bhagat?

Chandra Bhagat's historical performance shows significant declines in net sales and profits from March 2024 to March 2025, with net sales dropping from 221.37 Cr to 86.72 Cr and increasing debt levels from 16.43 Cr to 20.86 Cr, indicating a challenging financial environment.

Answer:<BR>The historical performance of Chandra Bhagat shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Chandra Bhagat's net sales peaked at 221.37 Cr in March 2024 but dropped to 86.72 Cr by March 2025. The total operating income followed a similar trend, decreasing from 221.37 Cr in March 2024 to 86.72 Cr in March 2025. The total expenditure also saw a decline, from 228.42 Cr in March 2024 to 88.18 Cr in March 2025. Operating profit (PBDIT) was negative in both March 2025 and March 2024, at -1.46 Cr and -7.05 Cr respectively, indicating a challenging operational environment. Profit before tax showed a slight decrease from 2.26 Cr in March 2024 to 1.17 Cr in March 2025, while profit after tax also fell from 1.53 Cr to 0.86 Cr in the same period. The company's total assets remained relatively stable, slightly decreasing from 101.78 Cr in March 2024 to 101.46 Cr in March 2025. Total debt increased from 16.43 Cr to 20.86 Cr, reflecting a rise in financial obligations. Cash flow from operating activities was consistent, with 6.00 Cr in March 2024 and 5.00 Cr in March 2023, but the net cash flow turned negative in March 2024 at -1.00 Cr. Overall, Chandra Bhagat's financial performance indicates a decline in sales and profits, alongside increasing debt levels, suggesting a need for strategic adjustments.

Which are the latest news on Chandra Bhagat?

Why is Chandra Bhagat falling/rising?

As of 03-Dec, Chandra Bhagat Pharma Ltd's stock price has fallen to Rs. 35.00, marking a 9.56% decrease and a new 52-week low. The stock has significantly underperformed compared to the Sensex, with a year-to-date decline of 46.97% and a 1-year drop of 49.13%.

As of 03-Dec, Chandra Bhagat Pharma Ltd's stock price is falling, currently at Rs. 35.00, which reflects a decrease of Rs. 3.7 or 9.56%. This decline is significant as it marks a new 52-week low for the stock. The performance today indicates that the stock has underperformed its sector by 9.55%. <BR><BR>Over the past week, the stock has decreased by 9.56%, while the benchmark Sensex has only fallen by 0.59%. In the last month, the stock has seen a decline of 14.88%, contrasting with a modest gain of 1.34% in the Sensex. Year-to-date, Chandra Bhagat's stock has plummeted by 46.97%, while the Sensex has increased by 8.92%. The longer-term performance is similarly concerning, with a 1-year decline of 49.13% compared to a 5.27% rise in the Sensex, and a staggering 68.78% drop over the past three years against a 35.37% increase in the benchmark.<BR><BR>Additionally, the stock has shown erratic trading behavior, having not traded on 5 out of the last 20 days. It opened with a loss of 9.56% today and has remained at this price level without any range. The stock is also trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a persistent downward trend. <BR><BR>Despite a rise in investor participation, with a 42.86% increase in delivery volume on November 24, the overall sentiment remains negative, contributing to the stock's decline.